P/E ratio for Nektar Therapeutics (NKTR)

P/E ratio history for Nektar Therapeutics from 2001 to 2023

PE ratio at the end of each year

P/E ratio for similar companies or competitors

Company	P/E ratio	P/E ratio differencediff.	Country
Amgen AMGN	20.5	-3,406.41%	🇺🇸 USA
Pfizer PFE	13.5	-2,280.46%	🇺🇸 USA
Merck MRK	54.8	-8,946.78%	🇺🇸 USA
Richardson Electronics RELL	11.4	-1,937.72%	🇺🇸 USA
AstraZeneca AZN	32.4	-5,324.52%	🇬🇧 UK
Baxter BAX	6.44	-1,139.87%	🇺🇸 USA
Alkermes ALKS	21.3	-3,538.77%	🇮🇪 Ireland
Johnson & Johnson JNJ	11.0	-1,881.69%	🇺🇸 USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.